The Filing Desk

Emergent BioSolutions

EBS · NYSE · Health Care · Financials, fiscal 2016 to 2025

EBS · Last close · November 19, 2026
$5.15
Value Emergent BioSolutions yourself

Emergent BioSolutions' revenue fell 28.8% to $743 million in fiscal 2025. Its operating margin was 13.5%, up from −10.4% a year earlier. Free cash flow was $157 million, up 338.0%. It paid out $25 million in dividends and buybacks, 16% of free cash flow. The diluted share count rose 7.0%.

EMERGENT BIOSOLUTIONS INC. Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001367644-26-000015 Updated
Revenue
$743M
28.8%
Operating margin
13.5%
23.9 pts
Net income
$53M
 
Free cash flow
$157M
338.0%
Return on capital
6.4%
13.3 pts
Market cap
$264M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Emergent BioSolutions does

Emergent BioSolutions sells products that respond to public health threats such as chemical, biological, radiological and nuclear attacks, emerging infectious diseases and drug overdose emergencies. It sells to governments, mainly the U.S. government, and to retail pharmacies.

It has three segments. The Commercial Product segment sells NARCAN and KLOXXADO, nasal sprays that reverse opioid overdoses. NARCAN is sold over the counter at retail pharmacies. The medical countermeasures (MCM) segment includes anthrax and smallpox products, as well as products for diseases such as mpox and Ebola. The Services segment is its contract development and manufacturing business, which it calls Bioservices.

The company earns revenue from selling its products, from its bioservices work for outside customers and from contract and grant funding for research. It says the revenue from its products is a substantial part of its total. It reports a portfolio of 11 products.

Its biggest risks, as it describes them

  • A substantial part of its revenue depends on U.S. government purchases, which need ongoing funding decisions.
  • It may not win new government contracts when current ones expire.
  • Failing to keep its manufacturing sites in compliance could damage its reputation and business.
  • Its biologic products must be shipped within set temperature ranges, or product can be lost.
From Emergent BioSolutions's annual report on Form 10-K, filed February 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share fell 2.1% a year and net income grew 0.2% a year, as new shares raised the share count by 15% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments576643112100205
Debt incl. finance leases8501,414868700590
Net debt (negative means net cash)274771757600384
Net debt to EBITDA0.6x——6,005.0x2.0x
Debt to equity0.5x1.0x1.3x1.4x1.1x
Interest coverage9.9x−4.6x−8.3x−1.5x1.7x
Current ratio3.4x1.0x1.0x3.7x5.0x
Quick ratio2.5x0.7x0.5x1.8x2.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Emergent BioSolutions' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Emergent BioSolutions shares on the open market, and 6 insiders sold $840,301, $577,200 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 1, 2026Paul Anthony WilliamsSVP, Products BusinessSold plan3,000$8.40$25,200Form 4
May 1, 2026Kathryn C ZoonDirectorSold plan17,202$8.40$144,453Form 4
May 1, 2026Donald W DeGolyerDirectorSold plan15,481$8.40$129,994Form 4
May 1, 2026Sujata Tyagi DayalDirectorSold plan13,761$8.40$115,610Form 4
Apr 30, 2026Keith KatkinDirectorSold plan15,481$8.28$128,183Form 4
Apr 1, 2026Paul Anthony WilliamsSVP, Products BusinessSold plan4,000$8.44$33,760Form 4
Dec 5, 2025Ronald RichardDirectorSold21,984$11.97$263,101Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 96 of 97 of 9
Rule of 40−30.7%2.9%−7.7%
Altman Z''−2.031.593.44
Accruals ratio−22.2%−15.5%−8.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassFailPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailPassFail
F-score3 of 96 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Emergent BioSolutions side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Emergent BioSolutionsFY25−28.8%13.5%21.1%6.4%2.0x7
Pacira BioSciencesFY253.6%2.6%18.8%1.1%1.2x9Compare
Corcept TherapeuticsFY2512.8%5.9%18.6%15.7%−8.1x3Compare
Amphstar PharmaceuticalsFY25−1.6%19.5%16.8%9.9%1.7x6Compare
Collegium PharmaceuticalFY2523.6%23.0%42.0%53.4%−0.4x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue4895617821,1061,5771,7741,1181,0491,044743
Revenue growth−6.5%14.8%39.5%41.4%42.6%12.4%−37.0%−6.1%−0.5%−28.8%
Gross profit362373460672925891383318362417
Research and development107971432262382351881117153
Operating income10612490114438341−170−726−109100
Net income52836354306220−212−760−19153
Diluted EPS (US$)1.131.711.221.045.684.06−4.22−14.85−3.600.93
Diluted shares (millions)49505152545450515357
Cash flow
Cash from operations5520842188537320−34−20659171
Capital expenditure76557287142224116522314
Free cash flow−22153−3010139596−150−25836157
Dividends paid0000000000
Share buybacks033000106820025
Acquisitions01188280000000
Stock-based compensation18152327524245231816
Balance sheet at fiscal year end
Cash and short-term investments272178112168621576643112100205
Debt incl. finance leases268148098228868501,414868700590
Total assets9701,0702,2292,3272,8832,9583,1661,8231,3901,319
Total liabilities3741581,2181,2391,4361,3461,7791,174907796
Shareholders' equity5969121,0111,0911,4511,6121,388649483523
Margins and ratios
Gross margin74.2%66.5%58.8%60.8%58.7%50.2%34.3%30.3%34.7%56.1%
Operating margin21.6%22.2%11.5%10.3%27.8%19.2%−15.2%−69.2%−10.4%13.5%
Net margin10.6%14.7%8.0%4.9%19.4%12.4%−18.9%−72.5%−18.3%7.1%
Free cash flow margin−4.4%27.3%−3.9%9.1%25.0%5.4%−13.4%−24.6%3.4%21.1%
Rule of 40 (growth + FCF margin)−10.9%42.1%35.6%50.5%67.7%17.9%−50.4%−30.7%2.9%−7.7%
Return on capital11.2%12.9%5.6%4.7%18.8%13.7%−6.6%−32.2%−6.9%6.4%
Return on equity8.2%10.9%6.5%5.2%24.1%14.3%−14.1%−74.7%−33.7%10.5%
Return on assets5.2%8.1%3.8%2.4%11.7%7.5%−6.9%−30.5%−11.9%3.9%
Net debt to EBITDA−0.0x−1.1x5.5x4.0x0.5x0.6x——6,005.0x2.0x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Emergent BioSolutions' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Emergent BioSolutions.